WO2002034282A3 - Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis - Google Patents

Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis Download PDF

Info

Publication number
WO2002034282A3
WO2002034282A3 PCT/US2001/045733 US0145733W WO0234282A3 WO 2002034282 A3 WO2002034282 A3 WO 2002034282A3 US 0145733 W US0145733 W US 0145733W WO 0234282 A3 WO0234282 A3 WO 0234282A3
Authority
WO
WIPO (PCT)
Prior art keywords
msp36
mammary
diagnosis
cancer treatment
secreted protein
Prior art date
Application number
PCT/US2001/045733
Other languages
French (fr)
Other versions
WO2002034282A2 (en
Inventor
Sam W Lee
Original Assignee
Beth Israel Hospital
Sam W Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Sam W Lee filed Critical Beth Israel Hospital
Priority to AU2002228730A priority Critical patent/AU2002228730A1/en
Publication of WO2002034282A2 publication Critical patent/WO2002034282A2/en
Publication of WO2002034282A3 publication Critical patent/WO2002034282A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are provided for using msp36 molecule, particularly an msp36 nucleic acid or protein, for treating and diagnosing a subject having or at risk of developing a cancer, particularly breast cancer.
PCT/US2001/045733 2000-10-27 2001-10-23 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis WO2002034282A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228730A AU2002228730A1 (en) 2000-10-27 2001-10-23 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24398200P 2000-10-27 2000-10-27
US60/243,982 2000-10-27

Publications (2)

Publication Number Publication Date
WO2002034282A2 WO2002034282A2 (en) 2002-05-02
WO2002034282A3 true WO2002034282A3 (en) 2003-05-01

Family

ID=22920906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045733 WO2002034282A2 (en) 2000-10-27 2001-10-23 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis

Country Status (2)

Country Link
AU (1) AU2002228730A1 (en)
WO (1) WO2002034282A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23102A1 (en) * 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech METHOD FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN THE MAMMARY GLAND OF NON-TRANSGENIC MAMMALS
CN1921892A (en) * 2003-10-17 2007-02-28 艾克蒂斯生物公司 Lentiviral vector delivery of msp36 for treatment of cancer
WO2007030651A1 (en) * 2005-09-08 2007-03-15 Actis Biologics, Inc. Mammary secreted protein for cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005416A2 (en) * 1998-07-23 2000-02-03 Georgetown University Fgf-bp promoter sequences as sensors of drug effects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005416A2 (en) * 1998-07-23 2000-02-03 Georgetown University Fgf-bp promoter sequences as sensors of drug effects

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CZUBAYKO F ET AL: "A SECRETED FGF-BINDING PROTEIN CAN SERVE AS THE ANGIOGENIC SWITCH IN HUMAN CANCER", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 10, October 1997 (1997-10-01), pages 1137 - 1140, XP002915489, ISSN: 1078-8956 *
HARRIS VIOLAINE K ET AL: "Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28539 - 28548, XP002209097, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2002034282A2 (en) 2002-05-02
AU2002228730A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2000055318A8 (en) Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2003055443A3 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2003087831A3 (en) Proteins involved in breast cancer
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
ATE318328T1 (en) DIAGNOSTICS AND THERAPEUTIC PRODUCTS FOR OSTEOPOROSIS
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002077176A3 (en) Aberrantly expressed proteins in laser capture microdissected tumors
AU5947701A (en) Methods for identification, diagnosis, and treatment of breast cancer
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
TR200000181T2 (en) Ligands containing antibodies that act against endocrine cells.
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2005030266A3 (en) Optical imaging of colorectal cancer
WO2001065998A3 (en) Methods for the diagnosis and treatment of breast cancer
WO2002034282A3 (en) Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
DE69938729D1 (en) METHOD FOR DIAGNOSIS OF BONE MEASURES FROM MALIGNANT TUMORS
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
WO2002086084A3 (en) Sequence characteristics of bladder cancer
EP1438431A4 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP